Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma Announces Financial Results for the First Half of 2026

A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy. * Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living with obesity or overweight.